Polar Capital Holdings PLC Bristol Myers Squibb CO Transaction History

Polar Capital Holdings PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $31.8 Million - $35 Million	-437,401 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $36.8 Million - $44.1 Million	-598,500 Reduced 57.78%	437,401 $31.9 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $39.7 Million - $46.3 Million	-740,367 Reduced 41.68%	1,035,901 $64.6 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $83 Million - $97.2 Million	1,402,425 Added 375.14%	1,776,268 $105 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $1.55 Million - $1.69 Million	25,000 Added 7.17%	373,843 $25 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $949,440 - $1.07 Million	16,000 Added 4.81%	348,843 $22 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $19.2 Million - $21.8 Million	332,843 New	332,843 $20.6 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.